


INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081		
				APPLICANT Leland SHAPIRO			
				FILING DATE March 3, 2000	GROUP 1646		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
/W.M./AA	4,021,472	5/3/77	Fuji et al				
	AB	4,051,842	10/4/977	Hazel et al.			
	AC	4,140,122	2/20/79	Kuhl et al.			
	AD	4,224,342	9/23/80	Fuji et al			
	AE	4,283,418	8/11/81	Fuji et al			
	AF	4,310,533	1/12/82	Uegai et al			
	AG	4,383,529	5/17/83	Webster			
	AH	4,629,567	12/16/86	Bollen et al.			
	AI	4,668,504	5/26/87	Kahan et al.			
	AJ	4,711,848	12/8/87	Insley et al.			
	AK	4,713,224	12/15/87	Tamhankar et al.			
	AL	4,732,973	3/22/88	Barr et al			
	AM	4,760,130	7/26/88	Thompson et al.			
	AN	4,788,603	11/29/88	Fujimura et al.			
	AO	4,829,052	5/9/89	Glover et al.			
	AP	4,839,283	6/13/89	Kawasaki et al			
	AQ	4,843,094	6/27/89	Imaki et al			
	AR	4,889,723	12/26/89	Kim et al			
	AS	4,931,279	6/5/90	Bawa et al.			
	AT	4,963,654	10/16/90	Katunuma			
	AU	5,004,612	4/2/91	Kim et al			
	AV	5,077,428	12/31/91	Imaki et al			
	AW	5,110,602	5/5/92	Kim et al			
	AX	5,157,019	10/23/92	Glover et al.			
	AY	5,175,253	12/29/92	Fallon et al.			
	AZ	5,214,191	5/25/93	Kirschenheuter et al			
	AAA	5,240,956	8/31/93	Kirschenheuter et al			
	AAB	5,247,084	9/21/93	Imaki et al			
/W.M./AAC	5,281,617	1/25/94	Kirschenheuter et al				
EXAMINER /William Moore/				DATE CONSIDERED 04/21/2009			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) 				ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081		
				APPLICANT Leland SHAPIRO			
				FILING DATE March 3, 2000	GROUP 1646		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
AAD	5,314,910	5/24/94	Kirschenheuter et al				
AAE	5,376,655	12/27/94	Imaki et al				
AAF	5,399,346	3/21/95	Anderson et al.				
AAG	5,416,191	5/16/95	Cheronis et al				
AAH	5,420,110	5/30/95	Miller et al.				
AAI	5,432,178	7/11/95	Nakai et al				
AAJ	5,470,970	11/28/95	Saeger et al.				
AAK	5,476,995	12/19/95	Clark et al				
AAL	5,478,727	12/26/95	Roizman et al				
AA M	5,486,470	1/23/96	Darke et al				
AAN	5,514,653	5/7/96	Perlmutter				
AAO	5,514,713	5/7/96	Nakai et al				
AAP	5,529,920	6/25/96	Cole et al.				
AAQ	5,532,215	7/2/96	Lezdey et al.				
AAR	5,565,334	10/15/96	Kufe et al				
AAS	5,593,858	1/14/97	Fleer et al				
AAT	5,604,201	2/18/97	Thomas et al.				
AAU	5,610,140	3/11/97	Goodfellow et al				
AAV	5,610,285	3/11/97	Lebing et al.				
AA W	5,614,555	3/25/97	Nakai et al				
AA X	5,616,693	4/1/97	Hwang et al.				
AA Y	5,618,792	4/8/97	Gyorkos et al.				
AA Z	5,622,984	4/22/97	Nakai et al				
ABA	5,635,593	6/3/97	Cheronis et al				
ABB	5,641,670	6/24/97	Treco et al				
ABC	5,663,416	9/2/97	Kirschenheuter et al				
EXAMINER /William Moore/				DATE CONSIDERED 04/21/2009			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081		
				APPLICANT Leland SHAPIRO			
				FILING DATE March 3, 2000	GROUP 1646		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	ABD	5,665,589	9/9/97	Harris et al			
	ABE	5,700,779	12/23/97	Goodfellow et al			
	ABF	5,710,026	1/20/98	Sprecher			
	ABG	5,712,117	1/27/98	Sprecher			
	ABH	5,747,645	6/6/98	Sprecher			
	AJL	5,750,506	5/12/98	Goodfellow et al			
	ABJ	5,759,548	6/2/98	Bathurst et al.			
	ABK	5,780,009	7/14/98	Karatzas et al			
	ABL	5,798,442	8/25/98	Gallant et al.			
ABM	5,801,148	9/1/??	Gyorkos et al				
ABN	5,807,829	9/15/98	Gyorkos et al				
ABO	5,811,241	9/22/98	Goodfellow et al				
ABP	5,817,484	10/6/98	Yu et al				
ABQ	5,834,431	11/10/98	Stewart et al				
ABR	5,843,900	12/1/98	Cheronis et al				
ABS	5,849,863	12/15/98	Stewart et al				
ABT	5,861,299	1/19/99	Archibald et al				
ABU	5,861,380	1/19/99	Gyorkos et al.				
ABV	5,863,899	1/26/99	Cheronis et al				
ABW	5,869,455	2/9/99	Gyorkos et al.				
ABX	5,874,424	2/23/99	Batchelor et al.				
ABY	5,891,852	4/6/99	Gyorkos et al				
EXAMINER	/William Moore/			DATE CONSIDERED	04/21/2009		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) 				ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081		
				APPLICANT Leland SHAPIRO			
				FILING DATE March 3, 2000	GROUP 1646		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation
							Yes
o BA		WO 98/56821	12/17/98	PCT			Abstr.
o BB		WO 98/20034	5/14/98	PCT			
o BC		WO 98/23565	6/4/98	PCT			
o BD		WO 98/50342	11/12/98	PCT			
o BE		WO 98/50420	11/12/98	PCT			
o BF		WO 97/21690	6/19/97	PCT			
o BG		WO 97/10231	3/20/97	PCT			
o BH		WO 97/03679	2/6/97	PCT			
o BI		WO 98/22619	5/28/98	PCT			
o BJ		WO 98/22098	5/28/98	PCT			
o BK		WO 97/48706	12/24/97	PCT			
o BL		WO 97/33996	9/18/97	PCT			
o BM		WO 98/46597	10/22/98	PCT			
o BN		WO 97/24339	7/10/97	PCT			Abstr.
o BO		WO 98/21186	5/22/98	PCT			
o BP		WO 98/09206	3/5/98	PCT			Abstr.
o BQ		WO 95/28422	10/26/95	PCT			
o BR		WO 95/34538	12/21/95	PCT			
o BS		WO 96/12021	4/25/96	PCT			
o BT		WO 96/14067	5/17/96	PCT			
o BU		WO 97/09346	3/13/97	PCT			
o BV		WO 97/09347	3/13/97	PCT			
o BW		WO 97/10222	3/20/97	PCT			
o BX		WO 97/31937	9/4/97	PCT			
o BY		WO 97/37969	10/16/97	WO			Abstr.
o BZ		WO 97/49679	12/31/97	WO			Abstr.
o BBA		WO 97/45402	12/4/97	WO			
o BBB		WO 98/06417	2/29/98	PCT			
o BBC		WO 98/49190	11/5/98	PCT			
EXAMINER /William Moore/				DATE CONSIDERED 04/21/2009			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
			APPLICANT Leland SHAPIRO	
			FILING DATE March 3, 2000	GROUP 1646
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
<input checked="" type="checkbox"/>	CA	Adelman S.F. et al., "Protease inhibitors suppress fibrinolytic activity of herpesvirus-transformed cells", <i>J Gen Virol</i> , 1982, 60(Pt 1):15-24.		
<input type="checkbox"/>	CB	Altieri, D.C. <i>J Leukoc Biol</i> 1995, 58, 120-127 pp. 120-127		
<input checked="" type="checkbox"/>	CC	Anderson ED, Thomas L, Hayflick JS, Thomas G., "Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant", <i>J Biol Chem</i> , 268(33):24887-91 (Nov 25, 1993)		
<input type="checkbox"/>	CD	Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. <i>Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo</i> . <i>Antimicrob Agents Chemother</i> 1995 Apr;39(4):846-9		
<input checked="" type="checkbox"/>	CE	Auerswald et al., "K15R M52E) aprotinin is a weak Kunitz-type inhibitor of HIV-1 replication in H9 cells" <i>Biomed Biochim Acta</i> , 1991, 50(4-6):697-700.		
<input type="checkbox"/>	CF	Auerswald et al., "Recombinant leech-derived trypsin inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication", <i>Biol Chem Hoppe Seyler</i> , 375(10):695-703 (1994)		
<input checked="" type="checkbox"/>	CG	Avril, et al., "Identification of the U-937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G", <i>FEBS Lett</i> , 1994, 345(1):81-6.		
<input type="checkbox"/>	CH	Avril LE, Di Martino-Ferrer M, Barin F, Gauthier F., "Interaction between a membrane-associated serine proteinase of U-937 monocytes and peptides from the V3 loop of the human immunodeficiency virus type I (HIV-1) gp120 envelope glycoprotein", <i>FEBS Lett</i> , 317(1-2):167-72 (Feb 8, 1993)		
<input type="checkbox"/>	CI	Banfi G, Pirali A, Locatelli M, Murone M, Bonini PA., "Tumor-associated trypsin inhibitor in induced and acquired immunodeficiency. Studies on transplanted and HIV-infected patients", <i>Scand J Clin Lab Invest</i> , 51 Suppl, 207:55-8 (1991)		
<input type="checkbox"/>	CJ	Beck, K.F. et al. in <i>J Exp Biol</i> 1999, 202, 645-653 pp. 645-653		
<input type="checkbox"/>	CK	Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. <i>J Virol</i> 1990 Feb;64(2):941-3		
<input checked="" type="checkbox"/>	CL	Bourinbaiar AS, Lee-Huang S., "Acrosin inhibitor, 4'-(acetamidophenyl 4-guanidinobenzoate, an experimental vaginal contraceptive with anti-HIV activity", <i>Contraception</i> , 51(5):319-22 (May 1995)		
<input checked="" type="checkbox"/>	CM	Bourinbaiar AS, Nagorny R., "Effect of serine protease inhibitor, N-alpha-tosyl-L-lysyl-chloromethyl ketone (TLCK), on cell-mediated and cell-free HIV-1 spread", <i>Cell Immunol</i> , 155(1):230-6 (Apr 15, 1994)		
EXAMINER <i>/William Moore/</i>			DATE CONSIDERED 04/21/2009	


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 DOL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) MAY 04 2001		ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
		APPLICANT Leland SHAPIRO	
		FILING DATE March 3, 2000	GROUP 1646
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
<input checked="" type="checkbox"/> English Abstract	CN	Bratt J, Palmblad J. <i>Cytokine-induced neutrophil 1 mediated injury of human endothelial cells.</i> <i>J Immunol</i> 1997 Jul 15; 159(2):812-8	
	CO	Brinkmann T, Schafers J, Gurtler L, Kido H, Niwa Y, Katunuma N, Tschesche H., "Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication of H9 cells by recombinant aprotinin and bikunin homologues", <i>J Protein Chem</i> , 16(6):651-60 (Aug 1997)	
	CP	Bristow CL, Fiscus SA, Flood PM, Arnold RR., "Inhibition of HIV-1 by modification of a host membrane protease", <i>Int Immunol</i> , 7(2):239-49 (Feb 1995)	
	CQ	Bukrinskaia AG, Korneeva MN, Nosik DN, Zhdanov VM., "Inhibition of HIV reproduction in cultured cells using proteolysis inhibitors", <i>Vopr Virusol</i> , 34(I):53-5 (Jan-Feb 1989) English Abstract only at page 55.	
	CR	Bukrinskaia AG, Kitsak Vla, Moisiadi SA, Arakelov SA. <i>Suppression of rotavirus SA-II reproduction by protease inhibitors in cell culture.</i> <i>Vopr Virusol</i> 1987 Jan-Feb;32(I):71-4 English abstract only at page 74.	
	CS	Carroccio A, Fontana M, Spagnuolo MI, Zuin G, Montaldo G, Canani RB, Verghi F, Di Martino D, Bastoni K, Buffardi F, Guarino A., "Pancreatic dysfunction and its association with fat malabsorption in HIV infected children", <i>Gut</i> , 43(4):558-63 (Oct 1998)	
	CT	Chesnokova NB, Maichuk YF. <i>Antiproteases in herpetic keratitis.</i> <i>Metab Pediatr Syst Ophthalmol</i> 1986;9(I):593-6	
	CU	Chesnokova NB, Kasavina BS, Maichuk luF, Kazachenko MA, Shchipanova Al. <i>Main proteolytic inhibitors in ocular herpes.</i> <i>Vopr Med Khim</i> 1981 Sep-Oct;27(5):663-5	
	CV	Cilberto et al., 1995, <i>Cell</i> , 41:531-540	
	CW	Cordiali Fei et al., "Behavior of several 'progression markers' during the HIV-Ab seroconversion period. Comparison with later stages", <i>J Biol Regul Homeost Agents</i> , 6(2):57-64 (Apr-Jun 1992)	
	CX	Cox et al., "Synergistic combinations and peptides in the inhibition of human immunodeficiency virus", <i>Adv Enzyme Regul</i> , 31:85-97 (1991)	
	CY	Deam DR, Byron KA, Ratnaike S, Campbell DG, Mulhall BP, Mackay IR., "Alpha I-antitrypsin phenotypes in homosexual men", <i>Pathology</i> , 21(2):91-2 (Apr 1989)	
	CZ	Decroy E, Wouters S, Di Bello C, Lasure C, Ruysschaert JM, Seidah NG., "Identification of the paired basic convertases implicated in HIV gp 160 processing based on in vitro assays and expression in CD4(+) cell lines", <i>J Biol Chem</i> , 271(48):30442-50 (Nov 1996)	
	CAA	Dery, O. and Bunnett, <i>N.W. Biochem Soc Trans</i> 1999, 27,246-254	
EXAMINER /William Moore/	DATE CONSIDERED 04/21/2009		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
			APPLICANT Leland SHAPIRO	
			FILING DATE March 3, 2000	GROUP 1646
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
B	CAB	Dery, O. et al. <i>Am J Physiol</i> 1998, 274, C 1429-C 1452		
*	CAC	DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizman B, Colonna RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. <i>Biol Chem</i> 1993 Jan 25;268(3):2048-51		
✓	CAD	Bilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonna RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. <i>J Biol Chem</i> 1994 Apr 29;269(17):12672-6		
*	CAE	Ding, A. et al., in <i>J. Immunol.</i> 1990, 145, 940		
✓	CAF	Estaqueir J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. <i>Blood</i> 1996 Jun 15;87(12):4959-66		
*	CAG	Flaitz CM, Hicks MJ. "Molecular piracy: the viral link to carcinogenesis." <i>Oral Oncol</i> 1998 Nov;34(6):448-53		
✓	CAH	Franzusoff A, Volpe AM, Josse D, Pichuantes S, Wolf JR., "Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing", <i>J Biol Chem</i> 1995 Feb 17;270(7):3154-9		
✓	CAI	Glozman VN, "Immunologic foundation of enzyme therapy of patients with ^{English} orchiepididymitis", <i>Antibiot Khimioter</i> , 35(7):50-52 (Jul 1990) abstract @ page 52.		
✓	CAJ	Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV 5 infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. <i>J Immunol</i> 1996 Oct 1;157(7):2754-2758		
*	CAK	Goureau, O. et al., in <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1993, 90, 4276		
✓	CAL	Griffin, William C. , "Calculation of HLB Values of Non-Ionic Surfactants", [H. L. B. - The Hydrophilic-Lipophilic Balance], <i>J. Soc. Cos. Met. Chem.</i> , Vol. 5, p. 249 (1954)		
✓	CAM	Gu M, Rappaport J, Leppla SH., "Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1", <i>FEBS Lett</i> , 22;365(I):95-7 (May 10, 1995)		
✓	CAN	Hallenger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W., "Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160", <i>Nature</i> , 26;360(6402):358-61(Nov 26, 1992)		
✓	CAO	Harvima et al., "Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein", <i>Biochem J</i> , 292 (Pt 3):711-8 (1993)		
*	CAP	Heck, D. E. et al., in <i>J. Biol. Chem.</i> 1990, 267, 21277		
EXAMINER		/William Moore/		
		DATE CONSIDERED		
		04/21/2009		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 <p style="text-align: center;">INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)</p>		ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
		APPLICANT Leland SHAPIRO	
		FILING DATE March 3, 2000	GROUP 1646
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
<input checked="" type="checkbox"/>	CAQ	Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. <i>Antiviral Res</i> 1997 Jun;35(1):1-21	
<input checked="" type="checkbox"/>	CAR	Inocencio et al., "Endoprotease activities other than furin and PACE4 with a role in processing of HIV-1 gp160 glycoproteins in CHO-K1 cells", <i>J Biol Chem</i> , 272(2):1344-8 (1997)	
<input checked="" type="checkbox"/>	CAS	Kamoshita K, Shiota M, Sasaki M, Koga Y, Okumura Y, Kido H., "Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase", <i>J Biochem</i> , Jun;117(6):1244-53 (Tokyo Jun 1995)	
<input checked="" type="checkbox"/>	CAT	Kennedy S, Davis C, Abrams WR, Billings PC, Nagashunmugam T, Friedman H, Malamud D., "Submandibular salivary proteases: lack of a role in anti-HIV activity", <i>J Dent Res</i> , 77(7):1515-9 (Jul 1998)	
<input checked="" type="checkbox"/>	CAU	Kido H, Fukutomi A, Katunuma N., "A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization", <i>J Biol Chem</i> , 15:265 (35):21979-85 (Dec 1990)	
<input checked="" type="checkbox"/>	CAV	Kido H, Niwa Y, Beppu Y, Towatari T. <i>Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul</i> 1996;36:325-47	
<input checked="" type="checkbox"/>	CAW	Kirkeboen, K.A. and Strand, O.A. in <i>Acta Anaesthesiol Scand</i> 1999, 43, 275	
<input checked="" type="checkbox"/>	CAX	Koito A, Hattori T, Murakami T, Matsushita S, Maeda Y, Yamamoto T, Takatsuki K., "A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of interalpha-trypsin inhibitor", <i>Int Immunol</i> , 1(6):613-8 (1989)	
<input checked="" type="checkbox"/>	CAY	Langer, R. <i>Nature</i> 1998, 392, 5 pp. 5-10	
<input checked="" type="checkbox"/>	CAZ	Lima AA, Silva TM, Gifoni AM, Barrett I-J, McAuliffe IT, Bao Y, Fox JW, Fedorko DP, Guerrant RL., "Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil", <i>Am J Gastroenterol</i> , 92(10):1861-6 (Oct 1997)	
EXAMINER <i>/William Moore/</i>		DATE CONSIDERED 04/21/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



**INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION
(PTO-1449)**

ATTY. DOCKET NO. 114232.104		SERIAL NO. 09/518,081
--------------------------------	--	--------------------------

APPLICANT Leland SHAPIRO	
-----------------------------	--

FILING DATE March 3, 2000	GROUP 1646
------------------------------	---------------

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<input checked="" type="checkbox"/>	CBA	Lomas DA, Elliott PR, Carrell RW. <i>Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.</i> Eur Respir J 1997 Mar;10(3):672-5
<input checked="" type="checkbox"/>	CBB	Lowenstein, C. J. and Snyder, S.H. in <i>Cell</i> 1992, 70, 705-707
<input checked="" type="checkbox"/>	CBC	Lowenstein C. J. et al. in <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 9730 - 9734 .
<input checked="" type="checkbox"/>	CBD	McCall, T.B. et al., in <i>Biochem. Biophys. Res. Commun.</i> 1992, 186, 680 - 685 .
<input checked="" type="checkbox"/>	CBE	McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM, "Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro", J Clin Invest, 96(1):456-64 (Jul 1995)
<input checked="" type="checkbox"/>	CBF	Meki AR, Mohey El-Dean ZM. <i>Serum interleukin-1beta, interleukin-6, nitric oxide and alpha1-antitrypsin in scorpion envenomed children.</i> Toxicon 1998 Dec;36(12):1851-9
<input checked="" type="checkbox"/>	CBG	Merrifield, R.B., "Solid Phase Peptide Synthesis. 1. The Synthesis of a Tetrapeptide", J. Am. Chem. Soc. Vol. 85, p. 2149-2154 (1963) pp. 2149-2154 (1963)
<input checked="" type="checkbox"/>	CBH	Meylan et al., "HIV infectivity is not augmented by treatment with trypsin, Factor Xa or human mast-cell tryptase", AIDS, 6(1):128-30 (1992)
<input checked="" type="checkbox"/>	CBI	Miranda et al., "Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes", Proc Natl Acad Sci U S A, 93(15):7695-7700) (1996)
<input checked="" type="checkbox"/>	CBJ	Molle W. et al. in <i>J Immunol</i> 1997, 159, 3555 - 3564 .
<input checked="" type="checkbox"/>	CBK	Moulard M, Achstetter T, Kieny MP, Montagnier L, Bahraoui E, "Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type I envelope glycoprotein precursor", Eur J. Biochem, 225(2):565-72 (Oct 15, 1994)
<input checked="" type="checkbox"/>	CBL	Nathan, C. in <i>FASEB J.</i> 1992, 6, 3051 - 3064
<input checked="" type="checkbox"/>	CBM	Novradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Tony Eissa N, Bames PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. <i>Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in alpha1-Antitrypsin Deficiency.</i> Am J Respir Cell Mol Biol 1999 Mar 1;20(3):441-447
<input checked="" type="checkbox"/>	CBN	Ohnishi et al., "A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type I", J Virol, 68(6):4075-99 (1994)
<input checked="" type="checkbox"/>	CBO	Okumura et al., "The extracellular processing of HIV- 1 envelope glycoprotein gp160 by human plasmin", FEBS Lett, 442(1):39-42 (1998)
<input checked="" type="checkbox"/>	CBP	Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S. <i>Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta.</i> Crit Care Med 1996 Nov;24(11):1903-7

EXAMINER

/William Moore/

DATE CONSIDERED

04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
		APPLICANT Leland SHAPIRO	
		FILING DATE March 3, 2000	GROUP 1646
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
<input checked="" type="checkbox"/>	CBQ	Patel R.P., et al. in <i>Biochim Biophys Acta</i> 1999, 1411, 385-400	
<input checked="" type="checkbox"/>	CBR	Patel T, Gores GJ, Kaufmann SH. <i>The role of proteases during apoptosis. FASEB J</i> 1996 Apr;10(5):587-97	
<input checked="" type="checkbox"/>	CBS	Pellegrini A, Thomas U, Franchini M, Stockli M, Klauser S, Hunziker P, von Fellenberg R. <i>Identification of an aprotinin antiviral domain. FEBS Lett</i> 1994 May 16;344(2-3):261-5	
<input checked="" type="checkbox"/>	CBT	Pezzilli R, Gullo L, Ricchi E, Costigliola P, Sprovieri G, Pilati G, Fontana G., "Serum pancreatic enzymes in HIV-seropositive patients", <i>Dig Dis Sci</i> , 37(2):286-8 (Feb 1992)	
<input checked="" type="checkbox"/>	CBU	Popko B. and Baerwald, K. D. in <i>Neurochem Res</i> 1999, 24, 33+ pages 331-338.	
<input checked="" type="checkbox"/>	CBV	Premack, B. A. and Schall, T. J., "Chemokine Receptors: Gateways to Inflammation and Infection", <i>Nature Medicine</i> , 2, 1174-1178 (1996)	
<input checked="" type="checkbox"/>	CBW	Pryor WA, Dooley MM, Church DF. <i>Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-l-proteinase inhibitor by nitric oxide/isoprene mixtures in air. Chem Biol Interact</i> 1985 Jul;54(2):171-83	
<input checked="" type="checkbox"/>	CBX	Punjabi, C. J. et al., in <i>J. Immunol.</i> 1992, 149, 2179 -2184 .	
<input checked="" type="checkbox"/>	CBY	Rehman A, Whiteman M, Halliwell B. <i>Scavenging of hydroxyl radicals but not of peroxy nitrite by inhibitors and substrates of nitric oxide syntheses. Br J Pharmacol</i> 1997 Dec; 122(8):1702-6	
<input checked="" type="checkbox"/>	CBZ	<i>Remington's Pharmaceutical Sciences</i> 1990, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA. [Nairn, J.G., Chapter 83]	
<input checked="" type="checkbox"/>	CCA	Scharpe S, De Meester I, Hendriks D, Vanhoof G, van Sande M, Vriend G, "Proteases and their inhibitors: today and tomorrow", <i>Biochimie</i> , 73(1):121-126 (Jan 1991)	
<input checked="" type="checkbox"/>	CCB	Schini et al. in <i>Circ Res</i> 1994, 74, 24 -32 .	
<input checked="" type="checkbox"/>	CCC	Schwartz, et al., "Antiviral activity of the proteasome on incoming human immunodeficiency virus type I", <i>J Virol</i> , 72(5):3845-50) (1998)	
<input checked="" type="checkbox"/>	CCD	Sharpstone D, Rowbottom A, Nelson M, Gazzard B. <i>Faecal alpha 1 antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals. Gut</i> 1996 Feb;38(2):206-10	
<input checked="" type="checkbox"/>	CCE	Shimizu T, Pommier Y. <i>DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res</i> 1996 Aug 1;226(2):292-301	
<input checked="" type="checkbox"/>	CCF	Sichko ZhV, Kozlova OL. <i>Experience in treating a herpetic infection with trypsin</i> [Article in Russian]. <i>Vrach Delo</i> 1991 Mar;(3):86-9 English Abstract Only	
EXAMINER William Moore/		DATE CONSIDERED 04/21/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION
(PTO-1449)

ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
--------------------------------	--------------------------

APPLICANT Leland SHAPIRO

FILING DATE March 3, 2000	GROUP 1646
------------------------------	---------------

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

English abstract at page 829.	CCG	Smith, M. E. in <i>Neurochem Res</i> 1999, 24, 261
	CCI	Szeghy G, Kenyeres B. <i>On the therapy of herpes simplex keratitis with heparin and trypsin</i> . [Article in German] <i>Klin Monatsbl Augenheilkd</i> 1968;153(6):827-30
	CCJ	Tang et al.; <i>Inactivation of HIV-1 by trypsin and its use in demonstrating specific virus infection of cells</i> , <i>J Virol Methods</i> 33(1-2):39-46 (Jun 1991)
	CCK	Turpin JA, Schaeffer CA, Bu M, Graham L, Buckheit RW Jr, Clanton D, Rice WG, <i>"Human immunodeficiency virus type-I (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor"</i> , <i>Antiviral Res</i> , 29(2-3):269-77 (Mar 1996)
	CCL	Van Molle W, Libert C, Fiers W, Brouckaert P. <i>Alpha I-acid glycoprotein and alpha I-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice</i> . <i>J Immunol</i> 1997 Oct 1;159(7):3555-64
	CCM	Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, Thomas G, Chretien M, Seidah NG, <i>"Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp 160 by the mammalian subtilisin/kexin-like convertases"</i> , <i>Biochem, J</i> ;314(Pt 2):521-32 (Mar 1996)
	CCN	Wood, E.R. et al. in <i>Biochem Biophys Res Commun</i> 1993, 191, 767-74
English abstract at page 36.	CCN	Zhirnov OP, Ovcharenko AV, Mel'nikova EE, Gaidamovich Sla, Bukrinskaia AG. <i>Antiviral activity of proteinase inhibitors in cultured cells infected with alpha-viruses</i> . <i>Mol Gen Mikrobiol Virusol</i> 1985 Dec;(12):30-6
EXAMINER <i>/William Moore/</i>	DATE CONSIDERED 04/21/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.